NICE was unable to develop medical technologies guidance on the OraQuick® HCV Rapid Antibody Test. Please contact medtech@nice.org.uk for more information.
NICE has since developed a Medtech Innovation Briefing (MIB24) on the technology.
| Status | Discontinued |
| Decision | Selected |
| Process | MTG |
| Referral date | 01 October 2010 |
| Topic area |
|
Provisional Schedule
| Topic Selection: | 16 December 2010 |
Email enquiries
- If you have any queries please email medtech@nice.org.uk
Stakeholders
If you would like to become a registered stakeholder in the development of guidance on this technology, please complete a stakeholder registration and confidentiality form (Word), and return to us at medtech@nice.org.uk.
Registered stakeholders will be informed of key stages in the development of guidance including when documents go out to consultation or comment.
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 May 2016 | Discontinued. NICE was unable to develop medical technologies guidance on the OraQuick® HCV Rapid Antibody Test. Please contact medtech@nice.org.uk for more information. NICE has since developed a Medtech Innovation Briefing (MIB24) on the technology. |
| 5 August 2011 | NICE's assessment of this medical technology is suspended. |
| 29 June 2011 | NICE is unable to develop medical technology guidance on OraQuick HCV Rapid Antibody Test because the manufacturer has decided not to pursue a submission for evaluation to the Medical Technologies Evaluation Programme (MTEP). NICE will therefore not be developing guidance on this topic. |
For further information on our processes and methods, please see our CHTE processes and methods manual